Cellular Health Screening Market: US$2.6B Valued, 9% Growth Expected in Next 5 Years

BRUSSELS - June 2, 2023 - PRLog -- Cellular health screening (https://meditechinsights.com/cellular-health-screening-market/) evaluates health determinants like lifestyle, environment, emotions, and diet. It assesses inflammatory conditions, autoimmune diseases, and gastrointestinal issues. The test monitors treatment progress, providing detailed reports for cellular-level improvement assessment. It determines cellular health, fat mass, fluid levels, toxicity, and muscle mass.

Advancements in cellular health screening to fuel the demand in the Cellular Health Screening Market

Advancements in cellular health screening tests have led to user-friendly and efficient tests with automated telomere identification, rapid results, and increased precision. These advancements give manufacturers a competitive edge, driving new product development. Some technological advancements include:

• In December 2022, Regenerus labs launched its TruAge Complete, an advanced epigenetic test that provide an accurate, comprehensive, and actionable analysis of a patient's biological ageing and health insights
• In August 2022, Proteomics International Laboratories announced the spin-off of an independent business for the commercialization of its patented '2-tag' technology developed together with The University of Western Australia

Increasing research activities to drive innovation in cellular health screening market

The cellular health screening market is driven by public awareness campaigns on chronic disease symptoms and prevention, reducing disease epidemics. Increased patient awareness and demand create a need for innovative screening kits and services. Researchers prioritize innovation, developing advanced diagnostic tests to meet the demand for cellular health screening. For Instance,

• In February 2023, Duke-NUS Medical School researchers, along with collaborators in Singapore, China, and the US, developed a precise and rapid test to measure the length of individual telomeres.
• In March 2021, Queen Mary University of London and Cardiff University researchers introduced HT-STELA, a rapid laboratory test for diagnosing telomeropathies. This DNA-based blood test enables high-throughput analysis of single telomere length, expanding its applicability to various sample types like fresh or frozen blood samples.
  
  

The cellular health screening market is set to gain momentum due to innovation, preventive healthcare acceptance, aging population growth, and geographic expansion by market players. By 2030, 1 in 6 people globally will be 60 or older, with the 60+ population increasing from 1 billion in 2020 to 1.4 billion. Aging raises chronic disease and infection risks, driving demand for preventive diagnostic tests and fueling the cellular health screening market growth.

Competitive landscape: Cellular Health Screening Market

The market is marked by the presence of key players such Quest Diagnostics (US); Telomere Diagnostics (US); SpectraCell Laboratories (US); Genova Diagnostics (US); LabCorp Holdings (US); Repeat Diagnostics, Inc. (Canada); Life Length (Spain); and others.

Get Detailed Insights on the Cellular Health Screening Market @ https://meditechinsights.com/cellular-health-screening-market/